A carregar...
Sorafenib and entecavir: The dioscuri of treatment for advanced hepatocellular carcinoma?
Hepatitis B virus (HBV) is responsible for 50%-80% of cases of hepatocellular carcinoma (HCC) worldwide. Entecavir (ET) is a potent inhibitor of chronic HBV-DNA polymerase, inhibiting both the priming and elongation steps of viral DNA replication. Sorafenib (SO) has proven efficacy in prolonging sur...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Baishideng Publishing Group Co., Limited
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3627877/ https://ncbi.nlm.nih.gov/pubmed/23599639 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v19.i14.2141 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|